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Abstract 
The central nervous system can act as a compartment in which HIV can replicate independently from plasma, and also as a 
sanctuary in which, under suboptimal drug pressure, HIV antiretroviral genetic variants can occur. Continuous replication of HIV in 
brain can contribute to neurocognitive impairment. Therefore, reaching adequate concentrations of antiretrovirals in the central 
nervous system might be essential in providing neuroprotection and improving neurocognition. Antiretrovirals have a restricted entry 
into the brain, due to several factors: the unique structure of the blood-brain barrier, and the existence of efficient efflux mechanisms. 
However, there is a high variability of antiretrovirals in reaching therapeutic drug concentrations in cerebrospinal fluid, that depend on 
the characteristics of the antiretrovirals (molecular weight, lipophilicity, protein binding) and on their capacity to be substrate for efflux 
transporters.  The review aims to discuss the main mechanisms that interfere with antiretroviral penetration into central nervous 
system, and to summarize the current data concerning the penetrability of different antiretrovirals into the cerebrospinal fluid. 
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Abbreviations: ART = antiretroviral treatment; ARV = antiretrovirals; NRTI = nucleos(t)idic reverse-transcriptase inhibitors; 
NNRTI = non-nucleosidic reverse transcriptase inhibitors; INNRT = integrase inhibitors; CNS = central nervous system; BBB 
= blood-brain barrier; CMT = carrier-mediated transport; AET = active efflux transports; PGP = P-glycoprotein; MRP = 
multidrug resistance-associated proteins; SLC = solute carriers;  
OATP = organic anion transporting polypeptide; OAT = organic anion transporters; OCT = organic cation transporters; EFV 
= Efavirenz; IDV = Indinavir; ZDV  = Zidovudine; d4T = Stavudine; ABC = Abacavir; ddI = Didanosine; 3TC = Lamivudine; 
TDF = Tenofovir; NVP = Nevirapine; PI = Protease inhibitors; APV = Amprenavir; NFV = Nelfinavir; SQV = Saquinavir; ATV 
= Ataznavir; TPV = Tipranavir; DRV = Darunavir; T20 = Enfuvirtide; RGV = Raltegravir  
Introduction 
Antiretroviral treatment (ART) represents a 
keystone in the evolution of HIV-infection by reducing 
mortality, increasing life span and quality. Nowadays, 
antiretrovirals (ARV) from six classes are available: 
nucleos(t)idic reverse-transcriptase inhibitors (NRTI), that 
interfere with reverse transcriptase by competing with the 
natural substrates and incorporating into viral DNA to act 
as chain terminators in the synthesis of proviral DNA; 
non-nucleosidic reverse transcriptase inhibitors (NNRTI)- 
that bind directly to the catalytic site of the reverse 
transcriptase, protease inhibitors (PI)- that inhibit the 
proteolitic cleavage of polipeptridic precursors, giving rise 
to noninfectious viral particles;  integrase inhibitors 
(INNRT) that block the integration of proviral DNA in the 
cell DNA, CCR5 co-receptor antagonists that prevent 
interaction of the V3 loop of gp120 with the CCR5 
coreceptor and fusion inhibitors that block entry of HIV 
into the target cell. Effectiveness of ART regimens is 
usually evaluated by measuring HIV RNA levels in 
plasma. However, there is evidence that HIV can replicate 
in compartments distinct from plasma [1] and can 
establish viral sanctuaries, with limited penetrations of 
antiretrovirals where viral replication continues during 
treatment, and ultimately determines occurrence of 
resistant HIV viral strains [2]. 
The central nervous system (CNS) is one of the 
compartments in which HIV determines an autonomous 
infection since the early stages of infection, but it is also a 
sanctuary in which HIV can independently replicate and 
has a genetic profile distinct from plasma, due to an 
inadequate concentration of ARV [3,4]. Neurocognitive 
impairment can be the result of HIV replication in the 
CNS, even in patients with suppressed plasma viral loads 
[5] and can interfere with the patient’s functionality [6].  Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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There seems to be a direct correlation between 
the concentrations of ARV in the CSF and the decrease of 
HIV CSF viral load [7,8]. Letendre developed and 
improved a quantification rank of antiretrovirals in CSF, 
which can be a useful tool for physicians in selecting the 
adequate ART for patients with neurocognitive impairment 
[8,9].  
This article intends to briefly present the factors 
that contribute to different concentrations of ARV in the 
CSF, and the current data concerning the penetrability of 
antiretrovirals in the CSF.  
 
Factors that influence the penetration of drugs across 
the blood-brain barrier 
The access of various molecules into the CNS is 
closely related to their ability to penetrate through the 
blood-brain barrier (BBB). The BBB consists of several 
compounds, two of which are better described: the 
vascular BBB primarily includes the cerebral capillaries 
and the endothelial cells sealed by tight junctions and the 
blood-CSF barrier represented mainly by the choroid 
plexuses, which form the interface between the blood and 
the ventricular cerebrospinal fluid [10].  
The penetrability of different drugs including ARV 
across the BBB is related to several characteristics like 
their physical and chemical particularities, their molecular 
weight, the protein binding, their lipid solubility, the degree 
of ionization, the molecular pumps mechanisms and also 
to the cerebral blood flow and the degree of local 
inflammation.  
Diffusion is one of the most common 
mechanisms of crossing the BBB [11]. Low molecular 
weight and higher lipid solubility facilitate a better 
penetration through the BBB. Conversely, high protein 
binding rates associated with low free drug levels diminish 
the penetration through the BBB.  
The efflux or influx transport mechanisms also 
play a crucial role in drug penetration into the CNS. The 
transporters are classified as carrier-mediated transport 
(CMT), active efflux transports (AET), and receptor-
mediated transport (RMT) [12]. CMT systems are 
generally responsible for the transport of nutrients 
(glucose, amino-acids) across the BBB. RMT are used to 
carry  endogenous large-molecule neuro-peptides, mainly 
hormones, into the brain by specialized ligand-specific 
receptor systems, including the insulin receptor, the 
transferrin receptor, the insulin-like growth factor receptor, 
the leptin receptor, the neonatal Fc receptor or the type BI 
scavenger receptor  [13]. However, the most important 
transporter mechanisms from the ARV perspective are 
the AET. Active efflux transporters limit the brain uptake 
of several high lipophilic drugs [14].  P-glycoprotein 
(PGP), multidrug resistance-associated proteins (MRP) 
are the best described energy-dependent efflux 
transporters that represent a major obstacle for ARV 
penetration in CNS. Solute carriers (SLC) are another 
group of efflux transporters especially designated for 
anions [15]. Members of this group include organic anion 
transporting polypeptide (OATP), organic anion 
transporters (OAT) and organic cation transporters (OCT). 
All these polypeptides are Na- and ATP-independent and 
they are expressed on the cell membrane of the 
endothelial capillaries in the brain. Choroid plexuses are 
also significantly involved in the cellular uptake of drugs, 
including ARV in the brain [16].   
 
Penetrability of ARV in CNS 
Antiretrovirals are following the same rules 
regarding their penetration in CNS. Table 1 shows the 
molecular weight, percentage of protein binding, range of 
plasma and CSF concentration. 
 
Table 1. Main properties of antiretrovirals 









Nucleos(t)ide  revers-transcriptase inhibitors 
Zidovudine (ZDV)  267.2  34-38  4.5-6.7 μmol/ml  0.12-0.41 μmol/ml 
Lamivudine (3TC)  229.3  <36  4.3-8.7 μmol/ml  0.05-1.14 μmol/ml 
Stavudine (D4T)  224.2  Negligible  3.3-6.4 μmol/ml  0.2-0.36 μmol/ml 
Didanosine (DDI)  236.2  <5  2.12-11 μmol/ml  0.17-0.51 μmol/ml 
Abacavir (ABC)  286.3  49  5.2-10.9 μmol/ml  0.5-1.8 μmol/ml 
Tenofovir disoproxil –TDF (PMPA 





     
Non-nucleosidic revers-transcriptase inhibitors 
Nevirapine (NVP)  266.3  60  7.5-16.9 μmol/ml  1.3-10.9 μmol/ml 
Efavirenz (EFV)  315.7  99.5  9.2-16.6 μmol/ml  0.006-0.09 μmol/ml 
Etravirine (ETV)  435  99.9  0,6 μmol/ml   Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Protease inhibitors 
Indinavir (IDV)  613.8  60  12.2-13.0 μmol/ml  0.03-0.66 μmol/ml 
Ritonavir (RTV)  721  98-99  10.5-26 μmol/ml  Nd-0.32 μmol/ml 
Nelfinavir (NFV)  567.8  >99  5.6-8.45 μmol/ml  Nd-0.012 μmol/ml 
Saquinavir (SQV)  670.9  98  1.84-3.23 μmol/ml  Nd-0.008 μmol/ml 
Amprenavir (APV)  505.6  90  10.6-19.2 μmol/ml  Nd-0.36 μmol/ml 
Lopinavir (LPV)  628.8  98-99  67945 ± 4215 μg/l  16.75 ± 8.6 μg/l 
Atazanavir (ATV)  704.9  ++(+)  128–6200 ng/ml  Nd–40 ng/ml 
Fosamprenavir - FPV(conveted rapidely to 
APV)  585.6  +++     
Darunavir (DRV)  548  95  1800–12900 ng/ml  15.9–212.0 ng/ml 
Entry inhibitors 
Enfuvirtide (T20)  446.2  +++  3.69 (SD 1.83) μg/mL  Nd 
Inhibitors of CCR5 co-receptors 
Maraviroc (MVC)  514  76  21.4–478.0 ng/ml  1.83–12.2 ng/ml 
Integrase inhibitors 
Raltegravir (RGV)  444  83  37–5180 ng/ml  2.0–126 ng/ml 
 
The levels of ART in the CSF are low compared 
to plasma. Nevertheless, the question is if these levels 
are enough to inhibit the replication of HIV in the CSF. 
Most studies use the half maximal inhibitory concentration 
(IC50) of the ART for the wild type HIV as reference. 
IC50, used for in vitro is comparable to the half maximal 
effective concentration (EC50) that represents the plasma 
concentration required for obtaining 50% of a maximum in 
vivo effect. However, IC90 and IC95 seem to be a better 
reference for the effectiveness of a specific drug.   
Table 1 shows that NRTI as class have the 
advantage of a good CSF concentration:  low molecular 
weight and the lowest rates of protein binding.  A study of 
NRTI penetrability in the CNS, based on sample collection 
at different time-points demonstrated that zidovudine has 
the best penetration rank followed by stavudine, 
didanosine and lamivudine [17]. Considering the same 
parameters (molecular weight and protein binding), 
nevirapine from the NNRTI class and indinavir from the PI 
class have the best probability of reaching good CSF 
levels.  
Zidovudine (ZDV) has the best partition 
coefficient in the brain and cerebral tissue, reflecting the 
lipid solubility of the compound [17]. ZDV is substrate for 
PGP, MRP-4 and MRP-5 [18]. One of the first studies on 
ZDV in CSF, demonstrated that penetration of ZDV into 
the CSF appeared to be dose independent, which may be 
an explanation for the efficacy of low doses of ZDV in the 
prevention and treatment of HIV-related neurological 
diseases [19]. Since the beginning of the HIV epidemic, 
treatment with ZDV was associated with decreased HIV 
RNA loads in CSF, less alteration of the brain tissue and 
improvement of neurocognitive performance in children 
with HIV encephalopathy [20].  
Stavudine (d4T) CSF stavudine concentrations 
reached or exceeded the mean concentration, producing 
50% of the maximal effect in vivo (EC 50) for HIV. Oatp-2 
like transporter has been implicated in its uptake [21]. 
ENT1 and ENT2 have been suggested as transporters for 
d4T on animal models [22].  
Abacavir (ABC) has moderate plasma protein 
binding and lipid solubility which account for a good CSF 
penetration rank. Animal models have shown that ABC 
reaches the brain, but not the CSF by a non-saturable 
mechanism, meaning that its transport across the BBB is 
not influenced by other drugs [23]. In an pharmacokinetics 
study on paired plasma-CSF from 54 patients, Caparelli 
et. al demonstrated a mean CSF/plasma ratio for ABC of 
36% that increased progressively with the augmentation 
of the doses, and showed that ABC penetrated into the 
CSF where it reached adequate concentrations which 
were able to inhibit the replication of HIV in the CNS [24]. 
Although a better CSF penetration compared to other 
antiretrovirals has been demonstrated for ABC, its lower 
penetration rate as compared to the corresponding free 
fraction indicated the possible existence of other active 
efflux mechanisms. In 2008, indeed, Giri et. al., 
demonstrated that PGP  is the dominant transporter 
limiting the CNS penetration of ABC [25].  
In animal models, Didanosine (ddI) was able to 
cross the BBB using saturable and non-saturable 
mechanisms [26]. ddI transport from the blood into the 
choroid plexuses involves an OATP 2-like transporter. In 
patients with HIV infection, ddI reaches relatively good 
CSF concentrations [27].  
Lamivudine (3TC) movement across the blood-
CSF barrier was examined in an isolated choroid plexus 
model, which showed low CSF accumulation of this 
molecule [28]. However, 3TC uptake from blood into the 
choroid plexus was significant, and it was facilitated by a 
digoxin-sensitive transporter. In the same study, 3TC had 
no major interactions with ABC. Based on rat models it is 
speculated that OCTs and probably OACT are involved in 
the cellular uptake of ZDV and 3TC [29].  
Tenofovir (TDF) reaches a CSF concentration of 
only 4% of the plasma concentration, suggesting a Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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passive or limited active transport and probably active 
efflux mechanisms from the CSF. These concentrations 
did not exceed IC50 for the wild-type; therefore, TDF is 
not suited for controlling CSF HIV replication [30]. 
However, studies on animal models demonstrated that 
although the transport of TDF in the CSF is minimal, the 
TDF precursor, PMPA, can reach the brain and 
accumulate in the choroid plexuses. These observations 
are related to the hydrophilic nature of PMPA and indicate 
the possible existence of a transporter at the choroid 
plexus site [31].  
Important differences have been observed 
among the NNRTI class representatives, concerning the 
penetration in CNS. It has been demonstrated that 
penetrability of Efavirenz (EFV) in CSF is limited. The 
efflux mechanism described was the induction of the 
expression and function of PGP [32]. EFV also inhibits 
MRP-1, MRP-2 and MRP-3 in a concentration-dependent 
manner [33]. In a small study on 9 patients, EFV levels 
were constantly less than 1% (0.61%, range 0.26%–
0.99%) of plasma levels [34]. However, in the same study, 
the authors found a mean EFV concentration of 35.1 nM 
(range 6.6–58.9 nM), that was above the IC95 of HIV wild 
type. This indicated that even if EFV was present in the 
CSF at low levels, these levels were effective in 
suppressing CSF viral levels when used in combination 
therapy. In a more recent report, Best et.al [35] have 
demonstrated that, even if EFV concentrations in CSF 
were only 0.5% of plasma concentrations they exceeded 
IC50 for the wild-type virus and were enough to inhibit the 
replication of HIV in the CSF.  
Nevirapine (NVP) crosses well the BBB [36], 
and maintains concentrations in CSF that remain stable in 
time [37]. NVP had the highest CSF/plasma penetrability 
rate when compared to other drugs [38]. NVP has the 
highest penetrability rank in Letendre’s classification [9], 
and therefore can be used in patients with neurocognitive 
impairment [8,39]. 
Protease inhibitors (PI) have good lipid 
solubility, and therefore they were expected to 
concentrate adequately in the brain, but, in fact, the CSF 
concentrations of these drugs are low [40]. The 
explanations for the limited penetrability of PIs in the CSF 
are:  the presence of efflux mechanisms (all the PIs are 
substrates for PGP) and high plasma protein binding (with 
the exception of Indinavir).  Boosting with low-dose 
ritonavir enhances PIs’ penetrability into the CSF [41,8].    
Indinavir (IDV) has the best CSF concentrations 
among all PIs [42-44]. This advantage can be explained 
by low protein-binding. Median concentration of IDV in 
CSF was 210 nmol/l [45], which is the threshold for IC95 
in vitro. IDV is essentially the only PI that reaches CSF 
concentrations above IC95 [46] [42]. From a clinical point 
of view, the presence of IDV in CSF was associated with 
significant improvement of neurocognitive performances 
[47].  
Concerning the other PIs, it has been 
demonstrated that their concentrations in CSF are enough 
to control viral replication although some of them 
concentrate poorly in CSF compared to plasma due to 
limited binding to plasma proteins, high molecular weight 
and efflux mechanisms.  A good example regarding this 
issue, is boosted Lopinavir (LPV/r) - Kaletra, one of the 
best characterized PIs in terms of CSF penetrability. 
Although LPV/r has a CSF/plasma penetration rate of 
0.22, its CSF levels are above IC50, [48,49]. Moreover, 
patients with monotherapy with LPV/r, and those with 
cART containing LPV/r [50] have a good decrease of HIV 
RNA in CSF and plasma and a reduction of the immune 
activation [50,51]. Because it penetrates the central 
nervous system in therapeutic concentrations and 
appears to reduce HIV replication in the central nervous 
system, LPV/r may benefit subjects who receive a 
diagnosis of or are at risk for HIV-associated 
neurocognitive disorders [51]. Similarly, Amprenavir 
(APV) boosted with low-dose RTV reaches CSF 
concentrations above IC50. In a study presented by 
Letendre et. al. [52], boosted or unboosted FPV had 
concentrations higher than IC50 with a CSF/plasma ratio 
of 0.45 – 1.30. 
Some PIs like Nelfinavir (NFV),  Saquinavir 
(SQV), Ataznavir (ATV) and Tipranavir (TPV) do not 
reach therapeutical concentrations in CSF [9]. CSF levels 
for NFV [53] and for SQV and RTV were below the 
detection limit [54]. For ATV, the CSF concentrations 
were highly variable and 100-fold lower than plasma 
concentrations, even with ritonavir boosting. CSF 
concentrations of ATV do not consistently exceed the 
wild-type IC50 of atazanavir and may not protect against 
HIV replication in the CSF [55]. 
In a recent study, Yilmaz et. al. [56] found 
detectable CSF Darunavir (DRV) levels in all the 
assessed patients. Most of them exceeded or remained in 
the same range as levels needed to inhibit the replication 
of the wild type virus, making it probable that DRV, at 
least to some extent, contribute to the suppression of HIV 
replication in the central nervous system. 
The penetrability of Enfuvirtide (T20) in the CSF 
is negligible and therefore in clinical settings, where direct 
CNS drug exposure is crucial, this drug is not likely to 
directly contribute to the local therapeutic effect [57]. 
Cases of virological failure secondary to selection of 
resistance mutations to T20 in CSF with consecutive loss 
of viral suppression in plasma have been described [58].  
Still, T20 is recommended for patients with HIV related 
neurocognitive impairment for its effect on the plasmatic 
pool, preferably in association with other three 
antiretrovirals with good CSF penetrability [57,59]. The 
motivation of this approach is due to the fact that 
antiretroviral treatment reduces immune activation with an 
indirect effect on the CNS in addition to the control of HIV 
replication in the plasma compartment [60].  Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Concerning the new antiretroviral drugs, data available to 
date suggest a good penetrability of integrase inhibitor 
and CCR5 co-receptors in the CSF.  
Raltegravir (RGV) demonstrated a good 
passage into CSF. In a study published in 2009 by Yilmaz 
and her collaborators, 50% of the CSF samples exceeded 
IC95. In addition to contributing to the control of systemic 
HIV-1 infection, raltegravir reaches local inhibitory 
concentrations in CSF in most, but not all, patients [61]. In 
a similar study, Letendre [62] detected RGV levels above 
IC50 in all CSF samples of 21 patients and the median 
concentration of RGV in the CSF was 14.5 ng/mL (IQR 
9.3 - 26.1, range 6.0 - 94.2). The median plasma 
concentrations were 260.9 ng/mL (IQR 72.0 - 640.4, 
range 17.8 - 4870). The CSF/plasma ratio was 5.8% (IQR 
2.1%- 17.8%, range 1.0%- 53.5%). Based on these 
results, RGV can be used as a component of regimens 
with good CSF penetrability.  
Studies regarding HIV tropism and coreceptors 
usage in the brain cells are limited. As microglia and 
monocyte-derived macrophages are the support of 
productive HIV infection in the CNS, and most likely play 
a major role in the development of HIV dementia, several 
studies were focused on the coreceptors used by these 
cells and they found that CCR5 is the main coreceptor 
used by HIV-1 isolated from the brain [63-65]. Tropism 
discordances between viral populations present in the 
CSF and in plasma have been observed. R5-tropic virus 
was usually found in the CSF [66,67]. Patients with 
advanced HIV disease [68] and especially those with HIV 
associated dementia had evidence of macrophage 
tropism and CCR5 use [69,70], but strains that use both 
CCR5 and CXCR4 co-receptors for cell entry have been 
identified in the brains of some individuals [71,72]. 
However, it seems that brain-derived Env’s still had 
preferential CCR5 usage [72]. 
The clinical consequences of virus populations 
with different tropism in specific body and cellular 
compartments as compared to the viral population in 
plasma are poorly understood [73-75]. Based on the 
observations that CCR5 receptors are mostly used in the 
brain of HIV-infected individuals and on studies that 
demonstrate that Maraviroc can reach adequate 
concentrations in CSF (above IC50) [76,77], the use of 
Maraviroc might be beneficial in patients with HIV-
associated CNS diseases, especially in those with 
neurocognitive impairment. Nevertheless, clinical trials 
are needed to demonstrate the effectiveness of Maraviroc 
in the brain and in order to answer the question if the 
brain can be considered a potential reservoir of CXCR4 
after exposure to CCR5 inhibitors.   
As antiretroviral drugs have limited penetration 
into the CSF, other alternative mechanisms have been 
studied in order to limit the viral replication and to provide 
neuroprotection. The alternatives designed “to cheat” the 
diffusion or efflux mechanisms are either ineffective [78] 
or too expensive (i.e. nanotechnology) [79,80]. On the 
other hand adjunctive therapies, like valoproic acid, 
lithium [81], minocycline [82-84] and other small 
molecules showed encouraging results in terms of 
improving neurocognition but are lacking longitudinal 
follow-up studies [85].  For example, minocycline, a 
second-generation tetracycline derivative, that has 
increased penetration in CNS, has been shown to 
decrease both the virus load in the cerebrospinal fluid and 
the brain, as well as the severity of CNS disease in a 
simian immunodeficiency virus macaque model of HIV-
associated neurological disease [82]. These, together with 
its immunomodulatory properties that reduce chronic 
activation and inflammatory processes may make it a 
promising adjuvant in active antiretroviral therapy.  
 
Summary and further research questions 
The efficacy of antiretroviral regimens in the CNS 
should concern every physician involved in the care of 
HIV-infected patients. This has become a requirement, as 
HIV-associated neurocognitive impairment nowadays 
involves mostly mild and moderate forms. Therefore, the 
diagnosis of neurocognitive impairment in an early stage 
is needed in order to give an ART regimen with good CSF 
penetrability rank, which will presumptively assure a 
degree of neuroprotection. 
Compartmentalization of HIV infection with 
genetic differences between plasma and CSF strains 
requires the quantification of HIV RNA and HIV resistance 
profile in both plasma and CSF and adjustment of ART 
regimen according to both results.   
The evaluation of efficacy of an antiretroviral 
regimen in CNS sanctuary requires beyond awareness on 
the penetrability and resistance mutations of ART in CSF, 
considering other factors as modification of BBB (e.g. 
inflammation), drug interactions and co-morbidities. CNS 
is a compartment where HIV enters in the early stages of 
infection and can undergo neuro-adaptation.  The unique 
structure of BBB and the existence of well-organized 
efflux mechanisms block or severely limit the access of 
ART.  Approaching this sanctuary is possible by 
medication with good lipid solubility, low molecular weight, 
and low plasma protein-binding that cannot be accessed 
by efflux transporters (either by avoiding or by blocking 
them).  However, further studies are needed to find an 
ideal drug to fulfil these criteria and assure a good 
balance between therapeutic effect and neurotoxicity. 
Longitudinal studies are needed to clarify if a 
neuro-cART can be protective for neurocognitive 
impairment in adults but also in the developing brain of 
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